Mono Pharmacare Limited — Important, 14-11-2024: Financial Result Updates

Consolidated financial results reveal strong performance for Mono Pharmacare Limited, reporting total revenue of ₹87.16 crore for the half year ended September 30, 2024. This reflects remarkable growth from ₹55.81 crore in the corresponding period last year. The revenue increase can be attributed to heightened demand in pharmaceutical distribution, along with strategic market expansion initiatives.

Net profit stands at ₹2.30 crore, compared to a loss of ₹0.58 crore year-over-year, indicating effective cost management, despite high operational expenses that rose by approximately 12% due to increased employee benefits and finance costs. The Earnings Per Share (EPS) has improved significantly to ₹1.30, showcasing a positive turnaround in profitability.

On the cost front, total expenses reached ₹84.05 crore, with employee benefits constituting a substantial portion, highlighting the company’s investment in human resources to drive growth. Given the operational efficiencies being employed, this increase in costs appears manageable.

Monetarily, the balance sheet reflects stable growth, with total assets amounting to ₹99.51 crore against liabilities of ₹30.42 crore. Cash flow analysis shows a net cash inflow from operating activities of ₹3.15 crore, supporting liquidity.

Strategically, Mono Pharmacare’s focus seems to be on enhancing distribution capabilities and expanding into new markets, positioning the company well for future growth. Investor sentiment appears favorable, making it a potential buy based on growth metrics and positive earnings trajectory.